National Psoriasis Foundation
Advertisement

Trial drug stays effective for psoriasis, even after a break

Melissa Leavitt

If you've ever taken a break from your psoriasis medication, you may wonder how well it will work when you start it again.

A Phase III trial for tofacitinib, an oral drug in development, tested the effects of restarting treatment after stopping for several months.

Almost two-thirds of patients whose skin significantly improved during their first course of treatment achieved similar results the second time around, according to findings presented by the drug manufacturer on May 23.

The trial involved 674 patients and lasted 14 months. For the first six months, patients were randomly assigned to take either a placebo or 5- or 10-milligram (mg) doses of the pill. Results showed that 68 percent of patients in the 10-mg group, and 44 percent in the 5-mg group, experienced a 75 percent reduction in psoriasis severity (or PASI 75, as measured by the Psoriasis Area and Severity Index). In addition, 63 percent of patients taking the 10-mg dose, and 42 percent taking the 5-mg dose, were assessed as having "clear" or "almost clear" skin.

Next, half of the patients who achieved these results were switched to a placebo until their psoriasis significantly worsened, or until four months had passed, whichever came first. At that point, they began taking tofacitnib again at their original dose for another four months.

After this second treatment period, 61 percent of patients taking the 10-mg dose, and almost 37 percent taking the 5-mg dose, regained PASI 75. More than 57 percent in the 10-mg group, and almost 45 percent in the 5-mg group, achieved "clear" or "almost clear" skin.

Tofacitinib targets Janus kinase, an enzyme linked to psoriasis inflammation. It is currently available in the U.S. under the brand name of Xeljanz for the treatment of rheumatoid arthritis.

Pfizer, the manufacturer of tofacitinib, plans to submit these results to the U.S. Food and Drug Administration, along with data from four other trials, by early 2015. Results from two other Phase III trials were released last month.

Advertisement


Did you enjoy this article? Want to read more?

Check out more from Psoriasis Advance »

Advertisement

 

Copyright © 1996-2013 National Psoriasis Foundation/USA

Any duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of National Psoriasis Foundation. National Psoriasis Foundation does not endorse or accept any responsibility for the content of external websites.

National Psoriasis Foundation | 6600 SW 92nd Ave., Suite 300, Portland, OR 97223
getinfo@psoraisis.org | www.psoriasis.org

National Psoriasis FoundationNational Psoriasis Foundation Our Mission: To drive efforts to cure psoriatic disease and improve the lives of those affected.

CONTACT US

getinfo@psoriasis.org
800-723-9166

National Office:
6600 SW 92nd Ave., Ste. 300
Portland, OR 97223


Washington D.C. Office:
1800 Diagonal Rd., Ste. 360
Alexandria, VA 22314


Site Feedback »

Copyright © 1996-2014 National Psoriasis Foundation/USA

Any duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of National Psoriasis Foundation.

The National Psoriasis Foundation does not endorse or accept any responsibility for the content of external websites.

The National Psoriasis Foundation does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

Member of Community Health Charities National Health CouncilFour Star Charity Navigator Rating